You are here: Industry Insights > Follicular lymphoma

News List

China's PI3K Inhibitors Have Made New Progress Since the Approval of Bayer's Copanlisib - Chiatai Tianqing's TQ-B3525 Is Proposed to Be Included in the Priority Review Dopine/PharmaSources
June 06, 2023
China's PI3K inhibitors have made new progress since the approval of Bayer's Copanlisib - Chiatai Tianqing's TQ-B3525 is proposed to be included in the priority review.
Innovent Announces Pivotal Phase 2 Results for Parsaclisib (PI3Kδ inhibitor) Presented at ASH 2021 Show Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma prnasia
December 14, 2021
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology...
Novartis’ CAR T therapy Kymriah shows promise in follicular lymphoma pharmatimes
June 04, 2021
Novartis’ CAR T therapy Kymriah has shown promise for the treatment of relapsed or refractory follicular lymphoma – the second most common form of non-Hodgkin lymphoma (NHL).
Yingli Pharma announce promising topline results of a Phase II registration study for treatment of relapsed/refractory follicular lymphoma with the once daily oral PI3Kδ inhibitor, linperlisib prnasia
April 01, 2021
Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma) announced topline results of a Phase II registration study of linperlisib, a PI3Kδ inhibitor, for the treatment of relapsed/refractory follicular lymphoma (FL).
Kite gets US FDA nod for Yescarta to treat relapsed or refractory follicular lymphoma expresspharma
March 08, 2021
Kite, a Gilead Company, announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two ...
Epizyme’s Tazverik secures FDA approval to treat follicular lymphoma pharmaceutical-technology
June 22, 2020
Epizyme has secured accelerated approval from the US Food and Drug Administration (FDA) for Tazverik to treat relapsed / refractory follicular lymphoma.
Kymriah Receives FDA Regenerative Medicine Advanced Therapy Designation americanpharmaceuticalreview
April 26, 2020
Novartis announced the US Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kymriah® (tisagenlecleucel).
Novartis’ Kymriah Gets RMAT Designation contractpharma
April 23, 2020
Investigational new indication to treat patients with relapsed or refractory follicular lymphoma.
Lenalidomide recommended for use with rituximab by NICE europeanpharmaceuticalreview
March 03, 2020
NICE has given its positive opinion to lenalidomide in combination with rituximab as a ‘chemotherapy-free’ treatment for lymphoma.
Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Follicular Lymphoma drugs
December 20, 2019
Epizyme, Inc., a late-stage biopharmaceutical company developing novel epigenetic therapies, announced that it has submitted a New Drug Application (NDA) to ...

Previous page 1 2 Next page